bioRxiv Science⌕ Search

Biology subjects

Avioz, T.

Publications and source records attributed to Avioz, T..

2 recordsLinked to original sources

EpiBinder: a multimodal framework for cell-type-specific prediction and interpretation of transcription factor binding

Transcription factor (TF) occupancy in vivo depends not only on the underlying DNA sequence but also on the local epigenetic environment, which varies across cell types and strongly influences whether sequence-encoded binding potential becomes functional. Here we present EpiBinder, a multimodal deep-learning framework for cell-type-specific prediction of TF binding that jointly models DNA sequence with base-resolution epigenetic information, including cytosine methylation from whole-genome bisulfite sequencing and chromatin accessibility from DNase I hypersensitivity data. Across multiple human cell lines, EpiBinder consistently outperforms strong sequence-only baselines, improving TF-binding prediction by up to 10% in area under the precision-recall curve. Beyond predictive performance, EpiBinder provides base-level attribution maps that enable systematic interrogation of regulatory context, including candidate methylation-sensitive loci, contextual motif dependencies, and putative TF-TF interactions. These results position EpiBinder as a practical framework for modeling and exploring the local regulatory grammar underlying cell-type-specific TF occupancy.

genomics↗

TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications

Approximately 50% of prostate cancer (PCa) patients harbor fusions involving the TMPRSS2 and ERG genes. Despite this, tailored therapies targeting the fused gene, tERG, remain undeveloped. Our study analyzed biopsy samples from two clinical trials assessing the efficacies of androgen receptor (AR) signaling inhibitors (ARSIs). The results revealed that tERG promotes resistance to ARSIs and is associated with elevated levels of the glucocorticoid receptor (GR). Subsequent assays showed that GR directly interacts with tERG, alleviates allosteric autoinhibition and prevents chemotherapy-induced tERG degradation. In PCa models, either inhibiting GR or lowering cortisol levels suppressed tumor growth in tERG-positive models, but not in fusion-negative models. In addition, patient-derived fusion-positive xenografts displayed enhanced sensitivity to combined GR and AR inhibitors. Collectively, these findings highlight TMPRSS2-ERG as a new biomarker and propose that simultaneous inhibition of GR and AR may specifically benefit tERG-positine patients. However, GR stimulatory corticosteroid therapies may not be advisable for this patient subgroup.

cancer biology↗